Skip to Content
Is your RA under control? Take an assessment and find out

Meloxicam Pregnancy and Breastfeeding Warnings

Meloxicam is also known as: Mobic, Vivlodex

Meloxicam Pregnancy Warnings

Meloxicam has been assigned to pregnancy category C prior to 30 weeks gestation and category D starting at 30 weeks gestation by the FDA. Animal data have revealed evidence of heart defects and embryolethality after extraordinary doses (64.5 times and 5.4 times the maximum recommended human dose (MRHD), based on body surface area conversions). Animal data have failed to reveal evidence of teratogenicity after oral doses equivalent to 2.2 times the MRHD; however there was an increased rate of stillbirths after oral doses that approximated the MRHD. Animal data have also revealed a reduction in birth index, live births, and neonatal survival at doses less than the MRHD. Meloxicam crosses the placental barrier. Prior to 30 weeks gestation, meloxicam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Starting at 30 weeks gestation, meloxicam and other NSAIDs should be avoided in pregnant women as premature closure of the ductus arteriosus in the fetus may occur. If meloxicam is used during this time period in pregnancy, the patient should be informed of the potential hazard to the fetus.

See references

Meloxicam Breastfeeding Warnings

There are no data on the excretion of meloxicam into human milk; however, meloxicam was excreted in the milk of lactating rats at concentrations higher than those in plasma. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the nursing mother.

See references

References for pregnancy information

  1. "Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.

References for breastfeeding information

  1. "Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.